Commercial flight and patients with intracranial mass lesions: A caveat. Report of two cases

Journal of Neurosurgery

Volumn 105, Issue 4, 2006, Pages 627-630

  Zrinzo, Ludvic U ^b   Crocker, Matthew ^a   Zrinzo, Laurence V ^b   Thomas, David G T ^b   Watkins, Laurence ^b  

^a NATIONAL HOSPITAL FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

^b NONE

Author keywords

Air travel; Cerebral edema; Intracranial pressure

Indexed keywords

DEXAMETHASONE; MANNITOL;

ADULT; ALTITUDE DISEASE; ANAMNESIS; ARTICLE; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FLIGHT; GLASGOW COMA SCALE; HUMAN; HYPERCAPNIA; INTRACRANIAL TUMOR; MALE; NEUROLOGIC DISEASE; NEUROLOGIC EXAMINATION; NUCLEAR MAGNETIC RESONANCE IMAGING; OXYGEN THERAPY; PRIORITY JOURNAL;

AIRCRAFT; ATMOSPHERIC PRESSURE; BRAIN EDEMA; BRAIN NEOPLASMS; CEREBRAL AQUEDUCT; CHOROID PLEXUS; DIAGNOSIS, DIFFERENTIAL; DISEASE PROGRESSION; FATAL OUTCOME; FEMALE; GRANULOMA; HUMANS; HYDROCEPHALUS; HYPOXIA, BRAIN; MAGNETIC RESONANCE IMAGING; MIDDLE AGED; RISK FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TRAVEL; XANTHOMATOSIS;

EID: 33749523215     PISSN: 00223085     EISSN: 00223085     Source Type: Journal    
DOI: 10.3171/jns.2006.105.4.627     Document Type: Article

References (22)

1. Andersson N, Grip H, Lindvall P, Koskinen LO, Brandstrom H, Malm J, et al: Air transport of patients with intracranial air: computer model of pressure effects. Aviat Space Environ Med 74:138-144, 2003
2. Committee on Air Quality in Passenger Cabins of Commercial Aircraft, Board on Environmental Studies and Toxicology, National Research Council: Pressure, in The Airliner Cabin Environment and the Health of Passengers and Crew. Washington, DC: National Academy Press, 2002, pp 34-38
3. Federal Aviation Administration: Allowable Carbon Dioxide Concentration in Transport Category Airplane Cabins. FR Doc 94-9759, filed 4-29-94. (http: //www.airweb.faa.gov/Regulatory_and_Guidance_Library/rgNPRM.nsf/2ed8a85bb3dd 48e68525644900598dfb/ef91755375b32ed385256923005b911a) [Accessed 10 August 2006]
4. Grissom CK, Roach RC, Sarnquist FH, Hackett PH: Acetazolamide in the treatment of acute mountain sickness: clinical efficacy and effect on gas exchange. Ann Intern Med 116:461-465, 1992
5. Grubb RL Jr, Raichle ME, Eichling JO, Ter-Pogossian MM: The effects of changes in PaCO2 on cerebral blood volume, blood flow, and vascular mean transit time. Stroke 6:630-639, 1974
6. Hackett PH: High altitude cerebral edema and acute mountain sickness. A pathophysiology update. Adv Exp Med Biol 474:23-45, 1999
7. Hackett PH: Subarachnoid cyst and ascent to high altitude - a problem? High Alt Med Biol 1:337-339, 2000
8. Hackett PH, Roach RC, Wood RA, Foutch RG, Meehan RT, Rennie D, et al: Dexamethasone for prevention and treatment of acute mountain sickness. Aviat Space Environ Med 59:950-954, 1988
9. Hackett PH, Yarnell PR, Hill R, Reynard K, Heit J, McCormick J: High-altitude cerebral edema evaluated with magnetic resonance imaging: clinical correlation and pathophysiology. JAMA 280:1920-1925, 1998
10. Hamilton AJ, Cymmerman A, Black PM: High altitude cerebral edema. Neurosurgery 19:841-849, 1986
11. Heiss JD, Papavassiliou E, Merrill MJ, Nieman L, Knightly JJ, Walbridge S, et al: Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor. J Clin Invest 98:1400-1408, 1996
12. Houston CS: High altitude illness. Disease with protean manifestations. JAMA 236:2193-2195, 1976
13. Johnson TS, Rock PB, Fulco CS, Trad LA, Spark RF, Maher JT: Prevention of acute mountain sickness by dexamethasone. N Engl J Med 310:683-686, 1984
14. Levine BD, Yoshimura K, Kobayashi T, Fukushima M, Shibamoto T, Ueda G: Dexamethasone in the treatment of acute mountain sickness. N Engl J Med 321:1707-1713, 1989
15. Machein MR, Kullmer J, Ronicke V, Machein U, Krieg M, Damert A et al: Differential downregulation of vascular endothelial growth factor by dexamethasone in normoxic and hypoxic rat glioma cells. Neuropathol Appl Neurobiol 25:104-112, 1999
16. Rock PB, Johnson TS, Cymerman A, Burse RL, Falk LJ, Fulco CS: Effect of dexamethasone on symptoms of acute mountain sickness at Pikes Peak, Colorado (4,300 m). Aviat Space Environ Med 58:668-672, 1987
17. Rock PB, Johnson TS, Larsen RF, Fulco CS, Trad LA, Cymerman A: Dexamethasone as prophylaxis for acute mountain sickness. Effect of dose level. Chest 95:568-573, 1989
18. Rodway GW, Hoffman LA, Sanders MH: High-altitude-related disorders - Part I: Pathophysiology, differential diagnosis, and treatment. Heart Lung 32:353-359, 2003
19. Ross RT: The random nature of cerebral mountain sickness. Lancet 8435:990-991, 1985
20. Severinghaus JW: Hypothetical roles of angiogenesis, osmotic swelling, and ischemia in high-altitude cerebral edema. J Appl Physiol 79:375-379, 1995
21. Shlim DR, Nepal K, Meijer HJ: Suddenly symptomatic brain tumors at altitude. Ann Emerg Med 20:315-316, 1991
22. Xu F, Severinghaus JW: Rat brain VEGF expression in alveolar hypoxia: possible role in high-altitude cerebral edema. J Appl Physiol 85:53-57, 1998